GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DMS Imaging SA (FRA:AS0) » Definitions » EBITDA Margin %

DMS Imaging (FRA:AS0) EBITDA Margin % : -0.19% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is DMS Imaging EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. DMS Imaging's EBITDA for the six months ended in Dec. 2023 was €-0.04 Mil. DMS Imaging's Revenue for the six months ended in Dec. 2023 was €19.75 Mil. Therefore, DMS Imaging's EBITDA margin for the quarter that ended in Dec. 2023 was -0.19%.


DMS Imaging EBITDA Margin % Historical Data

The historical data trend for DMS Imaging's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DMS Imaging EBITDA Margin % Chart

DMS Imaging Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 5.45 -3.55 4.98

DMS Imaging Semi-Annual Data
Dec13 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.54 -7.89 1.08 9.89 -0.19

Competitive Comparison of DMS Imaging's EBITDA Margin %

For the Biotechnology subindustry, DMS Imaging's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DMS Imaging's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DMS Imaging's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where DMS Imaging's EBITDA Margin % falls into.



DMS Imaging EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

DMS Imaging's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=2.022/40.564
=4.98 %

DMS Imaging's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-0.037/19.748
=-0.19 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


DMS Imaging  (FRA:AS0) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


DMS Imaging EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of DMS Imaging's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


DMS Imaging (FRA:AS0) Business Description

Traded in Other Exchanges
Address
7 Rue des Chasseurs Ardennais, Liege, BEL, 4031
DMS Imaging SA is a clinical-stage biopharmaceutical company. The company is engaged in the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies, based on its ASIT+ technology platform. Its lead product is gp-ASIT+, a phase III trial for the treatment of grass pollen rhinitis. Its pipeline products consist of hdm-ASIT+ for the treatment of house dust mite asthma; and pnt-ASIT+ for the treatment of peanut allergy.

DMS Imaging (FRA:AS0) Headlines

No Headlines